Hudson Sean A, Ecroyd Heath, Dehle Francis C, Musgrave Ian F, Carver John A
The University of Adelaide, South Australia, Australia.
J Mol Biol. 2009 Sep 25;392(3):689-700. doi: 10.1016/j.jmb.2009.07.031. Epub 2009 Jul 17.
The polyphenol (-)-epigallocatechin-3-gallate (EGCG) has recently attracted much research interest in the field of protein-misfolding diseases because of its potent anti-amyloid activity against amyloid-beta, alpha-synuclein and huntingtin, the amyloid-fibril-forming proteins involved in Alzheimer's, Parkinson's and Huntington's diseases, respectively. EGCG redirects the aggregation of these polypeptides to a disordered off-folding pathway that results in the formation of non-toxic amorphous aggregates. Whether this anti-fibril activity is specific to these disease-related target proteins or is more generic remains to be established. In addition, the mechanism by which EGCG exerts its effects, as with all anti-amyloidogenic polyphenols, remains unclear. To address these aspects, we have investigated the ability of EGCG to inhibit amyloidogenesis of the generic model fibril-forming protein RCMkappa-CN (reduced and carboxymethylated kappa-casein) and thereby protect pheochromocytoma-12 cells from RCMkappa-CN amyloid-induced toxicity. We found that EGCG potently inhibits in vitro fibril formation by RCMkappa-CN [the IC(50) for 50 microM RCMkappa-CN is 13+/-1 microM]. Biophysical studies reveal that EGCG prevents RCMkappa-CN fibril formation by stabilising RCMkappa-CN in its native-like state rather than by redirecting its aggregation to the disordered, amorphous aggregation pathway. Thus, while it appears that EGCG is a generic inhibitor of amyloid-fibril formation, the mechanism by which it achieves this inhibition is specific to the target fibril-forming polypeptide. It is proposed that EGCG is directed to the amyloidogenic sheet-turn-sheet motif of monomeric RCMkappa-CN with high affinity by strong non-specific hydrophobic associations. Additional non-covalent pi-pi stacking interactions between the polyphenolic and aromatic residues common to the amyloidogenic sequence are also implicated.
多酚(-)-表没食子儿茶素-3-没食子酸酯(EGCG)最近在蛋白质错误折叠疾病领域引起了广泛的研究兴趣,因为它对淀粉样β蛋白、α-突触核蛋白和亨廷顿蛋白具有强大的抗淀粉样活性,这些淀粉样纤维形成蛋白分别与阿尔茨海默病、帕金森病和亨廷顿病有关。EGCG将这些多肽的聚集重定向到无序的非折叠途径,导致形成无毒的无定形聚集体。这种抗纤维活性是特定于这些与疾病相关的靶蛋白还是更具普遍性,仍有待确定。此外,与所有抗淀粉样生成多酚一样,EGCG发挥其作用的机制仍不清楚。为了解决这些问题,我们研究了EGCG抑制通用模型纤维形成蛋白RCMκ-CN(还原和羧甲基化κ-酪蛋白)淀粉样生成的能力,从而保护嗜铬细胞瘤-12细胞免受RCMκ-CN淀粉样诱导的毒性。我们发现EGCG能有效抑制RCMκ-CN在体外形成纤维[50μM RCMκ-CN的IC(50)为13±1μM]。生物物理研究表明,EGCG通过将RCMκ-CN稳定在其天然样状态来防止其纤维形成,而不是通过将其聚集重定向到无序的无定形聚集途径。因此,虽然EGCG似乎是淀粉样纤维形成的通用抑制剂,但其实现这种抑制的机制特定于靶纤维形成多肽。有人提出,EGCG通过强非特异性疏水缔合以高亲和力定向到单体RCMκ-CN的淀粉样生成片-转角-片基序。淀粉样生成序列中常见的多酚和芳香族残基之间的额外非共价π-π堆积相互作用也有涉及。